ClinicalTrials.gg
RecruitingNCT05487391Updated Oct 15, 2024

A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection.

A Phase 3 interventional study of QL1706 injection and Vinorelbine Tartrate in Carcinoma, Non-Small-Cell Lung, sponsored by Qilu Pharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-15.

Sponsored by Qilu Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2022; still recruiting 3 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
632
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Carcinoma, Non-Small-Cell Lung by Qilu Pharmaceutical Co., Ltd. — 5 open to participants now, 8 under way, 3 of them phase 3. Carcinoma, Non-Small-Cell Lung · Qilu Pharmaceutical Co., Ltd..

Planned enrollment
Largest of 13
632 · median 176
Started
2022
with 2 others
Phase 3
4 of 14
1 open now
Registered
8th of 14
by date

Among the 14 studies in Carcinoma, Non-Small-Cell Lung by Qilu Pharmaceutical Co., Ltd., this one has the largest planned enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2022, is one of 4 in phase 3, and was the 8th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

5 of the 14 studies in Carcinoma, Non-Small-Cell Lung by Qilu Pharmaceutical Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Carcinoma, Non-Small-Cell Lung by Qilu Pharmaceutical Co., Ltd., or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of QL1706 combined with platinum-based chemotherapy versus placebo combined with platinum-based chemotherapy in adjuvant treatment of stage II-IIIB NSCLC without EGFR-sensitizing mutations and ALK fusions after complete surgical resection.The subjects were randomly divided into two groups according to 1:1, with about 316 subjects in the experimental group and the control group.

03

Conditions studied

  • Carcinoma, Non-Small-Cell Lung
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects voluntarily participated, signed an form (ICF), and were able to follow the study procedures.
  • Histopathologically confirmed squamous or non-squamous non-small cell lung cancer
  • Stage II-IIIB according to the 8th edition of the American Joint Committee on Cancer (AJCC) , and had received radical surgical resection (R0) treatment.
  • Participants were enrolled to receive therapy within 10 weeks after surgery (≤70 days) and had to recover sufficiently from surgery.
  • Non-squamous NSCLC subjects without EGFR-sensitizing mutation or ALK fusion gene.
  • (ECOG) performance status of 0 or 1.
  • Subjects (including women and men) agreed to use effective from the time of signing the informed consent to 180 days after the last use of the study drug.

Exclusion criteria

Exclusion Criteria:

  • Currently participating in and receiving study treatment or participating in an drug study and receiving study treatment or using an investigational device within 4 weeks prior to the first dose of study treatment.
  • Previous treatment with /adjuvant chemotherapy or therapy.
  • Cardiovascular and cerebrovascular diseases with clinical significance.
  • Gastrointestinal disease of clinical significance.
  • lung damage.
  • (HIV) antibody positive; Treponema pallidum antibody positive.
  • Active uncontrolled or active .
  • Administer a within 30 days prior to the first dose of study treatment.
  • Other occurred within 5 years prior to study enrollment. (Except: Bowen's disease; cured basal cell or squamous cell skin cancer; prostate cancer with a Gleason score of 6; treated cervical carcinoma in situ.)
  • Previously allergic to macromolecular protein preparations, or to any component of QL1706 and other investigational drugs; history of severe allergy to chemotherapy drugs (pemetrexed, vinorelbine, paclitaxel, cisplatin, carboplatin) or their preventive drugs, etc.
  • History of psychotropic substance abuse, alcohol or drug abuse; prior history of clear neurological or psychiatric disorders, including epilepsy or dementia.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
632 participants (estimated)

Study arms

  • Experimental
    QL1706 plus Platinum-based chemotherapy

    QL1706(5mg/kg Q3W IV) plus Platinum-based chemotherapy

    Drug: QL1706 injection · Drug: Vinorelbine Tartrate · Drug: Paclitaxel · Drug: Cisplatin · Drug: Carboplatin · Drug: Pemetrexed

  • Placebo comparator
    Placebo plus Platinum-based chemotherapy

    Placebo(5mg/kg Q3W IV) plus Platinum-based chemotherapy

    Drug: Vinorelbine Tartrate · Drug: Paclitaxel · Drug: Cisplatin · Drug: Carboplatin · Drug: Pemetrexed · Drug: Placebo

Interventions

  • QL1706(5mg/kg Q3W IV) concomitantly with Platinum-based chemotherapy

  • Vinorelbine 25mg/m2(D1、D8)Q3W IV, 2-4 cycles

  • Paclitaxel 175mg/m2(D1) Q3W IV, 2-4 cycles

  • Cisplatin 75mg/m2(D1)Q3W IV, 2-4 cycles

  • Carboplatin AUC=5(D1) Q3W IV, 2-4 cycles

  • Pemetrexed 500mg/m2(D1) Q3W IV, 2-4 cycles

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Disease-free Survival (DFS) in the PD-L1 ≥1% Population, Assessed by Investigator.

    DFS was defined as the time from randomization to first recurrence of NSCLC, appearance of new primary NSCLC, or death from any cause, whichever occurred first. Tumor recurrence includes local recurrence and distant metastasis.

    Time frame: Up to approximately 84 months

  2. Disease-free Survival (DFS) in the ITT Population, Assessed by Investigator.

    Time frame: Up to approximately 84 months

Secondary outcomes

  1. Overall Survival (OS)

    OS is defined as the time from random to death from any cause. OS will be measured in the PD-L1 subpopulation and in the ITT population.

    Time frame: Up to approximately 108 months

  2. Percentage of Participants Who are Survival at Year 4

    OS rates will be measured in the PD-L1 subpopulation and in the ITT population.

    Time frame: Year 4

  3. Percentage of Participants Who are Disease-Free at Year 3

    DFS rates will be measured in the PD-L1 subpopulation and in the ITT population.

    Time frame: Year 3

  4. Percentage of Participants Who are Disease-Free at Year 5

    DFS rates will be measured in the PD-L1 subpopulation and in the ITT population.

    Time frame: Year 5

  5. DFS Within Selected Populations

    Assessed by Investigator

    Time frame: Up to approximately 108 months

  6. Percentage of Participants with Adverse Events and Serious Adverse Events

    Time frame: Up to approximately 108 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2022 (actual). Primary completion is estimated for Aug 2027, 56 months after the start.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's planned 56 months is above that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 1, 2022
First posted
Aug 4, 2022
StartActual
Dec 8, 2022
Primary completionEst.
Aug 31, 2027
CompletionEst.
May 22, 2029
Last update
Oct 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05487391
Responsible party
Sponsor
First posted
Aug 4, 2022
Start date
Dec 8, 2022
Primary completion
Aug 31, 2027 (estimated)
Completion
May 22, 2029 (estimated)
Last update
Oct 15, 2024

Study contacts

Xiusong Qiu
Contact
xiusong.qiu@qilu-pharma.com
86-13918736645
Caicun Zhou, MD, PhD
study chair · Shanghai Pulmonary Hospital, Shanghai, China

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Iparomlimab/Tuvonralimab

Start the discussion